Abstract | PURPOSE: To evaluate the effects on 1-year event-free survival (EFS) and overall survival (OS) of combining motexafin and gadolinium (MGd), a potent radiosensitizer, with daily fractionated radiation therapy in children with newly diagnosed intrinsic pontine gliomas. METHODS AND MATERIALS: Patients with newly diagnosed intrinsic pontine glioma were treated with MGd daily for 5 consecutive days each week, for a total of 30 doses. Patients received a 5- to 10-min intravenous bolus of MGd, 4.4 mg/kg/day, given 2 to 5 h prior to standard dose irradiation. Radiation therapy was administered at a daily dose of 1.8 Gy for 30 treatments over 6 weeks. The total dose was 54 Gy. RESULTS: Sixty eligible children received MGd daily, concurrent with 6 weeks of radiation therapy. The estimated 1-year EFS was 18%±5%, and the estimated 1-year OS was 53%±6.5%. The most common grade 3 to 4 toxicities were lymphopenia, transient elevation of liver transaminases, and hypertension. CONCLUSIONS: Compared to historical controls, the addition of MGd to a standard 6-week course of radiation did not improve the survival of pediatric patients with newly diagnosed intrinsic pontine gliomas.
|
Authors | Kristin A Bradley, Tianni Zhou, Rene Y McNall-Knapp, Regina I Jakacki, Adam S Levy, Gilbert Vezina, Ian F Pollack |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 85
Issue 1
Pg. e55-60
(Jan 01 2013)
ISSN: 1879-355X [Electronic] United States |
PMID | 23092726
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2013 Elsevier Inc. All rights reserved. |
Chemical References |
- Metalloporphyrins
- Radiation-Sensitizing Agents
- motexafin gadolinium
|
Topics |
- Adolescent
- Brain Stem Neoplasms
(mortality, radiotherapy)
- Child
- Child, Preschool
- Disease-Free Survival
- Dose Fractionation, Radiation
- Drug Administration Schedule
- Female
- Glioma
(mortality, radiotherapy)
- Humans
- Hypertension
(chemically induced)
- Infant
- Infusions, Intravenous
- Liver
(enzymology)
- Lymphopenia
(chemically induced)
- Male
- Metalloporphyrins
(adverse effects, therapeutic use)
- Pons
- Radiation-Sensitizing Agents
(adverse effects, therapeutic use)
|